Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?-the SCOOP-2 trial experience.
作者信息
Peck-Radosavljevic Markus, Bota Simona, Hucke Florian
机构信息
Innere Medizin und Gastroenterologie (IMuG) mit Zentraler Aufnahme- und Erstversorgung (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
出版信息
Ann Transl Med. 2020 Nov;8(21):1340. doi: 10.21037/atm-2020-96.
Abstract
摘要
相似文献
1
Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?-the SCOOP-2 trial experience.
Ann Transl Med. 2020 Nov;8(21):1340. doi: 10.21037/atm-2020-96.
2
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
BMC Cancer. 2019 Oct 15;19(1):954. doi: 10.1186/s12885-019-6198-8.
3
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.
4
Current Status of Hepatic Arterial Infusion Chemotherapy.
Liver Cancer. 2015 Sep;4(3):188-99. doi: 10.1159/000367746. Epub 2015 Aug 12.
5
Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
World J Surg Oncol. 2019 Aug 15;17(1):143. doi: 10.1186/s12957-019-1685-6.
6
Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Jpn J Clin Oncol. 2019 Sep 1;49(9):845-855. doi: 10.1093/jjco/hyz069.
7
The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy.
Clin Cancer Drugs. 2015 Feb;2(2):112-118. doi: 10.2174/2212697X02666150602220735.
8
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
J Dig Dis. 2015 Sep;16(9):505-12. doi: 10.1111/1751-2980.12267.
9
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy.
World J Hepatol. 2018 Sep 27;10(9):571-584. doi: 10.4254/wjh.v10.i9.571.
10
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
Chin J Cancer. 2017 Oct 23;36(1):83. doi: 10.1186/s40880-017-0251-2.
引用本文的文献
1
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.
J Clin Med. 2025 Jan 7;14(2):314. doi: 10.3390/jcm14020314.
2
Analysis of risk factors of hepatocellular carcinoma and establishment of a clinical prognosis model.
Front Oncol. 2023 Mar 22;13:1067353. doi: 10.3389/fonc.2023.1067353. eCollection 2023.
3
Analysis of the role of m6A and lncRNAs in prognosis and immunotherapy of hepatocellular carcinoma.
Heliyon. 2022 Sep 14;8(9):e10612. doi: 10.1016/j.heliyon.2022.e10612. eCollection 2022 Sep.
本文引用的文献
1
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
BMC Cancer. 2019 Oct 15;19(1):954. doi: 10.1186/s12885-019-6198-8.
2
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
JAMA Oncol. 2019 Nov 1;5(11):1582-1588. doi: 10.1001/jamaoncol.2019.2792.
3
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.
4
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.
5
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.
6
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
7
Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.
Hepatology. 2018 Jan;67(1):422-435. doi: 10.1002/hep.29486.
8
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.
Liver Cancer. 2014 Oct;3(3-4):458-68. doi: 10.1159/000343875.
9
Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review).
Oncol Lett. 2012 Feb;3(2):259-263. doi: 10.3892/ol.2011.469. Epub 2011 Nov 2.
10
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
JAMA. 2010 Nov 17;304(19):2154-60. doi: 10.1001/jama.2010.1672.
Zotero 插件